Several generations of tyrosine kinase inhibitors (TKIs) have now been produced and examined for the treatment of EGFR mutant non-small cell lung cancer (NSCLC). Here, Nicolas Girard, MD, PhD, of Claude Bernard University, Lyon, France, discusses the different TKI treatment options at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland. He explores the varied benefits of gefitinib, erlotinib, afatinib and osimertinib, as well as the results of the FLAURA trial (NCT02296125), and the implications of these data on treatment sequencing.
Impact of new TKIs on NSCLC treatment planning
